Gerresheimer, a global systems and solutions provider for the pharma, biotech, and cosmetics industries, has published its first voluntary separate Non-financial Report for the 2025 financial year, aligned with the Corporate Sustainability Reporting Directive (CSRD). The audited report details the Group's sustainability performance, including a 31% reduction in scope 1 and scope 2 CO2e emissions compared to the 2019 base year, an increase in the share of electricity from renewable sources to 54% of total consumption, and a 63% improvement in the lost time incident rate (LTIR).
The company has also raised its CO2e reduction target for scope 1 and scope 2 emissions to -52% by 2030 and, for the first time, supplemented it with Scope 3 targets. These targets were externally validated by the Science Based Targets Initiative (SBTi). According to Wolf Lehmann, CFO of Gerresheimer AG, 'Despite a very challenging financial year in 2025, we significantly improved key sustainability metrics and, for the first time, reported on our sustainability performance in alignment with the CSRD. Our goal is to support our customers on their path toward increased sustainability.'
The report underscores Gerresheimer's commitment to measuring and managing climate protection and sustainability according to recognized standards. Beyond the CSRD-aligned report, the company discloses relevant data annually on the EcoVadis platform and as part of the CDP rating. In 2025, Gerresheimer was awarded a Gold rating by EcoVadis, scoring 78 out of 100, placing it among the top 4% of all evaluated companies and the top 1% in its industry. More than 150,000 companies are evaluated by EcoVadis each year.
In the CDP rating, Gerresheimer achieved an 'A-' in the climate category and 'Leadership' status for the second consecutive year. With over 22,100 companies assessed in 2025, Gerresheimer's result ranks above the global average (B) and the industry average (C). This recognition highlights the transparent disclosure of Gerresheimer's environmental management goals, processes, and results.
As part of its corporate strategy, Gerresheimer has set ambitious CO2e reduction targets validated by SBTi. By 2030, the company aims to reduce scope 1 and scope 2 emissions by 52% compared to 2019. Additionally, by the end of 2029, 65% of Gerresheimer's suppliers (based on spending on goods and services) are expected to set science-based climate targets. Finally, by 2034, the company aims to reduce emissions intensity relative to operating profit in selected scope 3 categories by 64% compared to the 2023 base year.
The implications of this report are significant for the industry and stakeholders. As regulatory pressure increases with the CSRD, Gerresheimer's proactive approach sets a benchmark for transparency and accountability. For customers in the pharma, biotech, and cosmetics sectors, this means access to more sustainable product options and reliable data to support their own sustainability goals. The improved safety metrics also signal a stronger focus on employee well-being, which can enhance worker morale and reduce operational risks.
Further information on Gerresheimer's sustainability strategy and performance is included in the 2025 Non-financial Report, available for download on the Gerresheimer website: https://www.gerresheimer.com/en/investors/investors-and-analysts/publications/reports.
